Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Immunovia Yönetim

Yönetim kriter kontrolleri 0/4

Immunovia's CEO'su Jeff Borcherding, Apr2023 tarihinde atandı, in görev süresi 1.5 yıldır. şirketin hisselerinin 0.21% doğrudan sahiptir ve bu hisselerin değeri € 16.32K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 2.4 yıldır.

Anahtar bilgiler

Jeff Borcherding

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jeff Borcherding (51 yo)

1.5yrs

Görev süresi

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeff Borcherding	Global Chief Executive Officer & President	1.5yrs	Veri yok	0.21% € 19.3k
Karin Liwendahl	Chief Financial Officer	2.5yrs	Veri yok	Veri yok
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.7yrs	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 1YR 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Hongaard Andersen	Independent Chairman	4.4yrs	SEK 475.00k	Veri yok
Hans Johansson	Independent Director	8.8yrs	SEK 280.00k	0.027% € 2.5k
Michael Lofman	Independent Director	1.4yrs	SEK 175.00k	Veri yok
Valerie Bogdan-Powers	Independent Director	less than a year	SEK 16.00k	Veri yok
Melissa Farina	Independent Director	less than a year	SEK 16.00k	Veri yok
Martin Moller	Independent Director	3.4yrs	SEK 302.00k	Veri yok

2.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1YR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Immunovia Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (Publ) Acquires All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic Cancer

Immunovia Completes Analytical Validation of Its Next-Generation Pancreatic Cancer Test

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.56 loss per share (vs kr4.00 loss in 2Q 2023)

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings released: kr7.43 loss per share (vs kr6.89 loss in FY 2021)

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings released: kr1.49 loss per share (vs kr2.18 loss in 2Q 2021)

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

First quarter 2022 earnings released: kr1.95 loss per share (vs kr1.04 loss in 1Q 2021)

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought €67k worth of stock

Independent Director recently bought €29k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş